MBNL-dependent impaired development within the neuromuscular system in myotonic dystrophy type 1.


Journal

Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829

Informations de publication

Date de publication:
02 2023
Historique:
revised: 27 10 2022
received: 18 09 2021
accepted: 12 12 2022
pubmed: 29 12 2022
medline: 3 3 2023
entrez: 28 12 2022
Statut: ppublish

Résumé

Myotonic dystrophy type I (DM1) is one of the most frequent muscular dystrophies in adults. Although DM1 has long been considered mainly a muscle disorder, growing evidence suggests the involvement of peripheral nerves in the pathogenicity of DM1 raising the question of whether motoneurons (MNs) actively contribute to neuromuscular defects in DM1. By using micropatterned 96-well plates as a coculture platform, we generated a functional neuromuscular model combining DM1 and muscleblind protein (MBNL) knock-out human-induced pluripotent stem cells-derived MNs and human healthy skeletal muscle cells. This approach led to the identification of presynaptic defects which affect the formation or stability of the neuromuscular junction at an early developmental stage. These neuropathological defects could be reproduced by the loss of RNA-binding MBNL proteins, whose loss of function in vivo is associated with muscular defects associated with DM1. These experiments indicate that the functional defects associated with MNs can be directly attributed to MBNL family proteins. Comparative transcriptomic analyses also revealed specific neuronal-related processes regulated by these proteins that are commonly misregulated in DM1. Beyond the application to DM1, our approach to generating a robust and reliable human neuromuscular system should facilitate disease modelling studies and drug screening assays.

Identifiants

pubmed: 36575942
doi: 10.1111/nan.12876
pmc: PMC10107781
doi:

Substances chimiques

RNA-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12876

Informations de copyright

© 2022 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

Références

Development. 2020 Nov 16;147(22):
pubmed: 33199350
Arch Neurol. 1973 Oct;29(4):215-22
pubmed: 4353847
Ann Neurol. 2013 Dec;74(6):862-72
pubmed: 23929620
Hum Mol Genet. 2009 Apr 15;18(8):1471-81
pubmed: 19223393
Curr Biol. 2015 Jun 15;25(12):1594-605
pubmed: 26051896
Curr Opin Genet Dev. 2017 Jun;44:135-140
pubmed: 28376341
Curr Opin Neurol. 2007 Oct;20(5):572-6
pubmed: 17885447
Science. 1992 Mar 6;255(5049):1253-5
pubmed: 1546325
Neural Dev. 2012 Feb 07;7:7
pubmed: 22314215
Clin Neurol Neurosurg. 2016 Nov;150:84-88
pubmed: 27611986
Muscle Nerve. 2006 May;33(5):627-36
pubmed: 16453325
Neurosci Res. 2013 May-Jun;76(1-2):10-5
pubmed: 23517713
Acta Neuropathol. 2021 Feb;141(2):257-279
pubmed: 33398403
Cell. 2008 Jul 11;134(1):175-87
pubmed: 18614020
Skelet Muscle. 2018 Jan 05;8(1):1
pubmed: 29304851
Cell Rep. 2015 Aug 18;12(7):1159-68
pubmed: 26257173
Nature. 2022 Mar;603(7899):124-130
pubmed: 35197626
J Neurol Neurosurg Psychiatry. 1987 Aug;50(8):1036-44
pubmed: 3655808
Hum Mol Genet. 2002 Apr 1;11(7):805-14
pubmed: 11929853
Cell. 1992 Apr 17;69(2):385
pubmed: 1568252
Mol Cell. 2002 Jul;10(1):35-44
pubmed: 12150905
J Neuropathol Exp Neurol. 2008 Aug;67(8):763-72
pubmed: 18648326
Front Neurol. 2018 May 18;9:349
pubmed: 29867749
Cell Stem Cell. 2011 Apr 8;8(4):434-44
pubmed: 21458401
J Anat. 1969 Jul;105(Pt 1):1-26
pubmed: 4184783
Neuron. 2005 Sep 1;47(5):667-79
pubmed: 16129397
Mol Brain. 2012 Feb 06;5:7
pubmed: 22309736
Nat Cell Biol. 2005 Dec;7(12):1240-7
pubmed: 16273094
Hum Mol Genet. 2021 Dec 17;31(1):41-56
pubmed: 34312665
Nat Commun. 2018 Jan 24;9(1):347
pubmed: 29367641
Stem Cell Res Ther. 2021 Dec 5;12(1):599
pubmed: 34865655
EMBO J. 2000 Sep 1;19(17):4439-48
pubmed: 10970838
iScience. 2019 Jan 25;11:258-271
pubmed: 30639849
Neurology. 2021 Feb 16;96(7):e1045-e1053
pubmed: 33472919
Elife. 2019 May 14;8:
pubmed: 31084710
Neuromuscul Disord. 2007 Mar;17(3):242-7
pubmed: 17306536
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cell. 2005 Feb 11;120(3):407-20
pubmed: 15707898
Cell. 2016 Jun 30;166(1):181-92
pubmed: 27321671
Brain. 1961 Mar;84:75-84
pubmed: 13764721
Neuropathol Appl Neurobiol. 2023 Feb;49(1):e12876
pubmed: 36575942
Proc Natl Acad Sci U S A. 2021 May 4;118(18):
pubmed: 33931501
Cell Stem Cell. 2022 Jan 6;29(1):11-35
pubmed: 34995492
Genes Dev. 2003 Feb 15;17(4):419-37
pubmed: 12600935
Nat Biotechnol. 2015 Jan;33(1):89-96
pubmed: 25383599
Mol Cell. 2002 Jul;10(1):45-53
pubmed: 12150906
SLAS Discov. 2018 Sep;23(8):790-806
pubmed: 29498891
Stem Cell Reports. 2020 May 12;14(5):892-908
pubmed: 32330447
Mol Ther. 2019 Aug 7;27(8):1372-1388
pubmed: 31253581
EMBO J. 2004 Aug 4;23(15):3103-12
pubmed: 15257297
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11748-53
pubmed: 16864772
Sci Adv. 2019 Jan 16;5(1):eaau7196
pubmed: 30746458
Cell. 2012 Aug 17;150(4):710-24
pubmed: 22901804
Front Pharmacol. 2021 Jan 14;11:617867
pubmed: 33519485
Nat Struct Mol Biol. 2010 Feb;17(2):187-93
pubmed: 20098426
Dev Neurobiol. 2018 Mar;78(3):331-339
pubmed: 29314718
Bioinformatics. 2011 Mar 15;27(6):863-4
pubmed: 21278185
Neuron. 2012 Aug 9;75(3):437-50
pubmed: 22884328
Eur J Neurosci. 2019 Jun;49(11):1491-1511
pubmed: 30667565
Handb Clin Neurol. 2013;113:1387-93
pubmed: 23622362
Sci Rep. 2012;2:209
pubmed: 22355723
Genome Res. 2015 Jun;25(6):858-71
pubmed: 25883322
EMBO Mol Med. 2013 Dec;5(12):1887-900
pubmed: 24293317

Auteurs

Julie Tahraoui-Bories (J)

INSERM/UEVE UMR 861, Université Paris Saclay, I-STEM, Corbeil-Essonnes, France.

Antoine Mérien (A)

INSERM/UEVE UMR 861, Université Paris Saclay, I-STEM, Corbeil-Essonnes, France.

Anchel González-Barriga (A)

INSERM, Institut de Myologie, Centre de Recherche en Myologie, Sorbonne Université, Paris, France.

Jeanne Lainé (J)

INSERM, Institut de Myologie, Centre de Recherche en Myologie, Sorbonne Université, Paris, France.

Céline Leteur (C)

CECS/AFM, I-STEM, Corbeil-Essonnes, France.

Hélène Polvèche (H)

CECS/AFM, I-STEM, Corbeil-Essonnes, France.

Alexandre Carteron (A)

CECS/AFM, I-STEM, Corbeil-Essonnes, France.

Juliette Duchesne De Lamotte (JD)

IPSEN Innovation, Les Ulis, France.

Camille Nicoleau (C)

IPSEN Innovation, Les Ulis, France.

Jérome Polentes (J)

CECS/AFM, I-STEM, Corbeil-Essonnes, France.

Margot Jarrige (M)

CECS/AFM, I-STEM, Corbeil-Essonnes, France.

Mário Gomes-Pereira (M)

INSERM, Institut de Myologie, Centre de Recherche en Myologie, Sorbonne Université, Paris, France.

Erwann Ventre (E)

CYTOO SA, Minatec, Grenoble, France.

Pauline Poydenot (P)

CYTOO SA, Minatec, Grenoble, France.

Denis Furling (D)

INSERM, Institut de Myologie, Centre de Recherche en Myologie, Sorbonne Université, Paris, France.

Laurent Schaeffer (L)

INMG, INSERM U1217, CNRS UMR5310, Université Lyon 1, Université de Lyon, Hospices Civils de Lyon, Lyon, France.

Claire Legay (C)

CNRS, SPINN-Saint-Pères Paris Institute for the Neurosciences, Université Paris Cité, Paris, France.

Cécile Martinat (C)

INSERM/UEVE UMR 861, Université Paris Saclay, I-STEM, Corbeil-Essonnes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH